Review article · 2022 · Open access

A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies

Jennifer L. Dashnau, Qiong Xue, Monica Nelson, Eric Law, Lan Cao, Derek J. Hei

Cytotherapy, 25(1), 1–13 · Published 13 September 2022 · DOI 10.1016/j.jcyt.2022.08.001

Open full textCite this paper

In brief

“A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies” is a 2022 review article by Jennifer L. Dashnau and 5 co-authors, published in Cytotherapy. OpenAlex counts 34 citations as of 21 November 2026, which puts it in the top 7% of works published in 2022 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cytotherapy.

Citations
34
Most cited in
2025 (12)
Field-weighted impact
0.62
References
77
Authors
6

Abstract

Advances in cellular reprogramming and gene-editing approaches have opened up the potential for a new class of ex vivo cell therapies based on genetically engineered, induced pluripotent stem cell (iPSC)-derived allogeneic cells. While these new therapies share some similarities with their primary cell-derived autologous and allogeneic cell therapy predecessors, key differences exist in the processes used for generating genetically engineered, iPSC-derived allogeneic therapies. Specifically, in iPSC-derived allogeneic therapies, donor selection and gene-editing are performed once over the lifetime of the product as opposed to as part of the manufacturing of each product batch. The introduction of a well-characterized, fully modified, clonally derived master cell bank reduces risks that have been inherent to primary-cell derived autologous and allogeneic therapies. Current regulatory guidance, which was largely developed based on the learnings gained from earlier generation therapies, leaves open questions around considerations for donor eligibility, starting materials and critical components, cell banking and genetic stability. Here, a risk-based approach is proposed to address these considerations, while regulatory guidance continues to evolve.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dashnau, J. L., Xue, Q., Nelson, M., Law, E., Cao, L., & Hei, D. J. (2022). A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies. Cytotherapy, 25(1), 1–13. https://doi.org/10.1016/j.jcyt.2022.08.001

MLA 9

Dashnau, Jennifer L., et al. “A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies.” Cytotherapy, vol. 25, no. 1, 2022, pp. 1–13. https://doi.org/10.1016/j.jcyt.2022.08.001.

Chicago

Dashnau, Jennifer L., Qiong Xue, Monica Nelson, Eric Law, Lan Cao, and Derek J. Hei. 2022. “A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies.” Cytotherapy 25 (1): 1–13. https://doi.org/10.1016/j.jcyt.2022.08.001.

Harvard

Dashnau, J. L. et al. (2022) ‘A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies’, Cytotherapy, 25(1), pp. 1–13. doi:10.1016/j.jcyt.2022.08.001.

IEEE

J. L. Dashnau, Q. Xue, M. Nelson, E. Law, L. Cao, and D. J. Hei, “A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies,” Cytotherapy, vol. 25, no. 1, pp. 1–13, 2022, doi: 10.1016/j.jcyt.2022.08.001.

BibTeX

@article{dashnau2022risk,
  title     = {{A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies}},
  author    = {Dashnau, Jennifer L. and Xue, Qiong and Nelson, Monica and Law, Eric and Cao, Lan and Hei, Derek J.},
  journal   = {Cytotherapy},
  year      = {2022},
  volume    = {25},
  number    = {1},
  pages     = {1--13},
  doi       = {10.1016/j.jcyt.2022.08.001},
  url       = {https://doi.org/10.1016/j.jcyt.2022.08.001}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202333
20241111
20251212
202688

Its field-weighted citation impact is 0.62: it has been cited 0.62 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • risk-based approach
  • genetically modified cells
  • induced pluripotent stem cells
  • cell line development
  • master cell bank
  • donor eligibility
  • genome editing
  • genetic stability

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Dashnau, J. L., Xue, Q., Nelson, M., Law, E., Cao, L., & Hei, D. J. (2022). A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies. Cytotherapy, 25(1), 1–13. https://doi.org/10.1016/j.jcyt.2022.08.001

How many times has this paper been cited?

34 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cytotherapy: sign in and open the full text from this page.

Who wrote this paper?

Jennifer L. Dashnau, Qiong Xue, Monica Nelson, Eric Law, Lan Cao, Derek J. Hei.

What is the DOI of this paper?

10.1016/j.jcyt.2022.08.001, permanently at https://doi.org/10.1016/j.jcyt.2022.08.001. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.